Genetic risk factors for drug-induced long QT syndrome : findings from a large real-world case-control study
Aim: Drug-induced long QT syndrome (diLQTS), an adverse effect of many drugs, can lead to sudden cardiac death. Candidate genetic variants in cardiac ion channels have been associated with diLQTS, but several limitations of previous studies hamper clinical utility. Materials & methods: Thus, the purpose of this study was to assess the associations of KCNE1-D85N, KCNE2-I57T and SCN5A-G615E with diLQTS in a large observational case-control study (6,083 self-reported white patients treated with 27 different high-risk QT-prolonging medications; 12.0% with diLQTS). Results: KCNE1-D85N significantly associated with diLQTS (adjusted odds ratio: 2.24 [95% CI: 1.35-3.58]; p = 0.001). Given low minor allele frequencies, the study had insufficient power to analyze KCNE2-I57T and SCN5A-G615E. Conclusion: KCNE1-D85N is a risk factor for diLQTS that should be considered in future clinical practice guidelines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 25(2024), 3 vom: 20. Feb., Seite 117-131 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lopez-Medina, Ana I [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Arrhythmia |
|---|
| Anmerkungen: |
Date Completed 22.03.2024 Date Revised 28.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/pgs-2023-0229 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369959132 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369959132 | ||
| 003 | DE-627 | ||
| 005 | 20240329000905.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240320s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2023-0229 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM369959132 | ||
| 035 | |a (NLM)38506312 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lopez-Medina, Ana I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genetic risk factors for drug-induced long QT syndrome |b findings from a large real-world case-control study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2024 | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: Drug-induced long QT syndrome (diLQTS), an adverse effect of many drugs, can lead to sudden cardiac death. Candidate genetic variants in cardiac ion channels have been associated with diLQTS, but several limitations of previous studies hamper clinical utility. Materials & methods: Thus, the purpose of this study was to assess the associations of KCNE1-D85N, KCNE2-I57T and SCN5A-G615E with diLQTS in a large observational case-control study (6,083 self-reported white patients treated with 27 different high-risk QT-prolonging medications; 12.0% with diLQTS). Results: KCNE1-D85N significantly associated with diLQTS (adjusted odds ratio: 2.24 [95% CI: 1.35-3.58]; p = 0.001). Given low minor allele frequencies, the study had insufficient power to analyze KCNE2-I57T and SCN5A-G615E. Conclusion: KCNE1-D85N is a risk factor for diLQTS that should be considered in future clinical practice guidelines | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a KCNE1-D85N | |
| 650 | 4 | |a arrhythmia | |
| 650 | 4 | |a drug-induced long QT syndrome | |
| 650 | 4 | |a pharmacogenomics | |
| 650 | 4 | |a torsade de pointes | |
| 650 | 7 | |a Potassium Channels, Voltage-Gated |2 NLM | |
| 700 | 1 | |a Campos-Staffico, Alessandra M |e verfasserin |4 aut | |
| 700 | 1 | |a A Chahal, Choudhary Anwar |e verfasserin |4 aut | |
| 700 | 1 | |a Volkers, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Jacoby, Juliet P |e verfasserin |4 aut | |
| 700 | 1 | |a Berenfeld, Omer |e verfasserin |4 aut | |
| 700 | 1 | |a Luzum, Jasmine A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 25(2024), 3 vom: 20. Feb., Seite 117-131 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:3 |g day:20 |g month:02 |g pages:117-131 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2023-0229 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 3 |b 20 |c 02 |h 117-131 | ||